1. Scrip
  2. >>Business

Juvenescence Raises $100M To Advance Anti-Aging Programs

 
• By Scrip Team

The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.

Age_100
Juvenescence backing longevity start-ups • Source: Shutterstock

Juvenescence Ltd. has raised $100m in a Series B financing round to fund its portfolio of anti-aging startups through to initial value inflection points.

UK-based Juvenescence, which was co-founded by biotech investor Jim Mellon, used the first $65m it raised to build out a globe-spanning network of R&D programs focused on extending healthy lifespans....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.